1 – 10 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Copy number signatures for early diagnosis of high-grade serous ovarian carcinoma
2022) “FUTURE PERSPECTIVES IN OVARIAN CANCER RESEARCH”(
- Contribution to conference › Poster
- 2020
-
Mark
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
(
- Contribution to journal › Article
- 2019
-
Mark
Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration
(
- Contribution to journal › Article
-
Mark
Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
(
- Contribution to journal › Article
- 2018
-
Mark
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
(
- Contribution to journal › Article
-
Mark
Claudin-4 Expression is Associated with Survival in Ovarian Cancer but Not with Chemotherapy Response
(
- Contribution to journal › Article
-
Mark
Abstract P3-02-02: Concordance between immunohistochemical and gene-expression based subtyping of early breast cancer using core needle biopsies and surgical specimens - experices from SCAN-B
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
- 2017
-
Mark
Involvement of chromatin remodeling genes and the Rho GTPases RhoB and CDC42 in ovarian clear cell carcinoma
(
- Contribution to journal › Article
-
Mark
Claudin-4 expression is associated with progression free survival in ovarian cancer, but not with chemotherapy response
(
- Contribution to journal › Article